PolynovoASX:PNV +1.65%77 FCF Yield % is 0.82 as of Jun. 29, 2026. GuruFocus rates ASX:PNV with a GF Score™ of 77/100 and a GF Value™ of A$3.24 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Polynovo ranks better than 58.31% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Polynovo's FCF Yield % or its related term are showing as below:
ASX:PNV'
s FCF Yield % Range Over the Past 10 Years
Min: -5.53 Med: -0.74 Max: 0.82
Current: 0.82
During the past 13 years, the highest FCF Yield % of Polynovo was 0.82%. The lowest was -5.53%. And the median was -0.74%.
ASX:PNV's FCF Yield % is ranked better than 58.31% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: -0.385
vs ASX:PNV: 0.82
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Polynovo FCF Yield % Related Terms
Polynovo FCF Yield % Historical Data
* Premium members only.
The historical data trend for Polynovo's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Polynovo's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Polynovo's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo (ASX:PNV) has a FCF Yield % of 0.82 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Polynovo and its competitors. According to the industry distribution chart, Polynovo ranks #356 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 41.7%.
Is Polynovo's FCF Yield % too high?
Polynovo's current FCF Yield % is 0.82. Based on the distribution chart, Polynovo ranks #356 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Polynovo has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #356 out of 854 companies for FCF Yield %. This puts Polynovo in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Polynovo and its competitors. Polynovo's current FCF Yield % is 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (ASX:PNV) is currently considered Significantly Undervalued. The stock's GF Value™ is A$3.24, compared to a current price of A$0.93 — trading 71.5% below its estimated fair value. The current FCF Yield % is 0.82. Polynovo's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Polynovo (ASX:PNV), the current FCF Yield % is 0.82 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (ASX:PNV) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of A$0.93 is trading 71.5% below its estimated GF Value™ of A$3.24.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for ASX:PNV:
FCF Yield %: 0.82
GF Value™: A$3.24 vs. price of A$0.93 (71.5% below fair value)
No single metric tells the full story. See the ASX:PNV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
77GF Score
Get the complete analysis for ASX:PNV
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PNV has been successfully added to your 
